Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers

Stopped The study was terminated after the second cohort had completed Part II due complex PK results. There were no safety concerns.

Conditions

• Healthy

Interventions

• DRUG: ODM-108 Part I
• DRUG: Placebo Part I
• DRUG: ODM-108-Part II
• DRUG: Placebo Part II
• DRUG: ODM-108 Part III
• DRUG: Midazolam

Sponsor

Orion Corporation, Orion Pharma

Collaborators

• [object Object]